Home > News > Olfaction in Parkinson’s Disease – A Clinical Approach
Parkinson's Disease
Read Time: 6 mins

Olfaction in Parkinson’s Disease – A Clinical Approach

Published Online: November 23rd 2020 European Neurological Review. 2020;15(1):37–40 DOI: https://doi.org/10.17925/ENR.2020.15.1.37
Authors: Antje Haehner, Thomas Hummel, Heinz Reichmann
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Olfactory loss is one of the major non-motor symptoms of Parkinson’s disease (PD). Olfactory assessment constitutes an important part of PD diagnostic procedures in many clinics. The majority of patients present with severe quantitative olfactory loss, with accompanying qualitative smell disorders being very rare. Olfactory subfunctions are differentially impaired in PD compared with other hyposmic individuals whereby the impairment in odour discrimination turned out to have predictive value in preclinical PD. In terms of PD risk stratification in patients with unexplained smell loss, a clear diagnostic allocation based on an exhaustive clinical assessment and comprehensive chemosensory testing seems to be essential. This brief review summarises relevant information about olfactory dysfunction in PD and discusses the diagnostic utility of olfactory testing for early PD diagnosis.

Keywords

Smell, olfaction, Parkinson’s disease

Article:

Olfactory loss has been extensively studied in Parkinson’s disease (PD) and is now widely acknowledged as one of the major non-motor symptoms of the disease, which precedes the occurrence of clinical motor symptoms.1,2 It is found in around 90% of patients with PD,3–5 and has been considered as a supportive criterion in clinical PD diagnosis according to the International Parkinson’s Disease and Movement Disorder Society diagnostic criteria.6 In this article, we briefly review alterations in the olfactory system and then highlight clinical criteria of smell loss in PD. The focus is on how a reliable PD risk stratification could be achieved based on olfactory symptoms.

Lack of specific changes in olfactory peripheral structures

Exposed to the external environment, the olfactory epithelium allows pathogen penetration into the brain, which might induce numerous symptoms of PD according to the vector hypothesis.7 Therefore, the olfactory system could be one of the peripheral sites where PD first develops.8 However, there is little, and inconsistent, information on changes at the olfactory periphery. While several human case-control studies have published gut microbiome composition changes in PD,9 it is less clear whether differences exist between PD and healthy controls for nasal microbiota composition.10,11 Also, the presence of alpha-synuclein in the olfactory epithelium is still controversially discussed. While it was not detected in olfactory epithelium biopsies of patients with PD,12 alpha-synuclein was found in olfactory cells in PD autopsy cases.13 Further, in vivo examinations of the olfactory epithelium revealed histological changes comparable to other causes of smell loss,12 which suggest non-specific peripheral changes in the olfactory system
in PD.

Changes at the level of the olfactory bulb and alterations in central olfactory processing

At the level of the olfactory bulb, PD seems to differ from other causes of olfactory loss. In all aetiologies involving ‘peripheral’ olfactory loss (such as posttraumatic, postinfectious, or sinonasal smell disorders14–17), but also in more ‘central’ pathologies above the level of the olfactory bulb (such as depression,18 schizophrenia,19 and temporal lobe epilepsy20), a very clear and consistent correlation between olfactory function and olfactory-bulb volume can be observed, suggesting that smell loss comes along with a measurable olfactory-bulb volume loss. In PD, however, the volume of the olfactory bulb appears to be deviating from this rule. Despite of the severity of olfactory impairment in PD, it remains a matter of debate whether patients with PD present with decreased olfactory bulb volumes compared with age-matched controls. So far, a number of recent studies have reported conflicting results: while some studies reported an overall reduction of
olfactory-bulb volume in PD,21,22 the vast majority of studies question any olfactory-bulb volume differences between PD and healthy controls.23–26 This is in line with findings of an increased number of olfactory dopaminergic periglomerular cells in patients with PD,27,28 which might underlie hyposmia in patients with PD.

However, in regions related to both primary (piriform cortex, amygdala) and secondary integrative (orbitofrontal cortex) olfactory processing, a significant atrophy was found in PD, which correlated with olfactory performance.29–31 This might suggest that central olfactory areas in PD seem to represent the degree of disease progression, whereas this correlation is not seen in peripheral olfactory structures. In line with this, previous results based on a large 64-channel olfactory event-related potential study indicate major alterations in central olfactory processing in PD compared with people with hyposmia of different origin.32

Character of smell loss in Parkinson’s disease

Virtually all studies performed since the 1970s have shown olfactory disturbances in patients with PD. Published data on the prevalence of olfactory dysfunction in PD range from 45% in early studies,33 up to 74% in the work of Hawkes et al.,4 or as high as over 90%;3,5 the latter of which is currently considered to be a realistic percentage. The majority of patients with PD with smell loss (>80%) are already functionally anosmic or severely hyposmic at the time of testing, regardless of the type of olfactory test being used for diagnosis. In contrast to other causes of smell loss, only very few patients present with accompanying parosmia, or phantosmia.5 Olfactory impairment seems to be associated with PD subtype and gender, resulting in a less pronounced smell loss in patients with tremor-dominant type34,35 and in women.36,37 The majority of studies based on psychophysical testing methods failed to show a disease duration-related progression of olfactory loss,4,5,38,39 whereas some authors reported an association between disease severity and smell loss.39–41 The latter was confirmed by an imaging study using dopamine transporter single-photon emission computed tomography (DaT-SPECT), indicating that a more pronounced olfactory dysfunction was associated with greater loss of nigrostriatal dopamine neurons.42 Additionally, non-motor symptoms, like cognitive impairment, depression, anxiety and sleep disturbances, which are typically related to PD severity, are associated with the degree of olfactory loss.39,42 This allows us to consider olfactory function a marker of disease progression.

Olfactory loss in PD has a general character: all three olfactory qualities (threshold, discrimination and identification) are involved. There is evidence that patients with PD perform relatively well in odour threshold testing, but poorly in odour identification and discrimination compared with other aetiology groups of hyposmia.43 Although only a comprehensive approach allows a precise evaluation of olfactory function, short identification tests might be considered a sufficient screening measurement with good discriminating abilities.44,45 Earlier studies have reported selective olfactory deficits and described certain odours to have discriminative value for PD, e.g., pizza or banana.46–48 Other studies argue strongly against selective anosmia or hyposmia in PD, suggesting that the odour identification problem is a general one.45,49

Until now, there were no convincing data indicating that dopaminergic treatment would improve olfactory function;50–52 although deep brain stimulation might affect odour discrimination abilities.53,54 However, in a study in more than 200 patients with PD, positive effects of rasagiline treatment on odour discrimination abilities were found in patients with early PD only.55 Among non-pharmacological treatments, there is convincing evidence that structured training with odours significantly increases olfactory function in PD,56,57 suggesting that olfactory training might be a promising approach already known from current otorhinolaryngology recommendations.58

The association of Parkinson’s disease and idiopathic smell loss

Several population-based studies have already pointed out the association between unexplained smell loss and later development of PD.59–62 In terms of PD risk stratification, a clearly diagnosed idiopathic smell loss based on an exhaustive clinical assessment according to the current diagnostic otorhinolaryngological criteria seems to be absolutely essential. Data from a large patient cohort study from a Smell & Taste Clinic suggest a 10% rate of PD development among patients with diagnosed idiopathic olfactory loss, with a further increase in risk to 28.9% in those with a combined olfactory and gustatory loss.63 Thus, current findings imply the need for both olfactory and gustatory testing in a PD at-risk population. A further clinically relevant observation might be that smell loss is characterised by further deterioration prior to PD diagnosis resulting in a 2.5-fold higher PD risk in those patients, compared with other individuals with idiopathic hyposmia.63

The duration of the hyposmic phase prior to PD diagnosis is still a matter of debate.64 In many previous studies investigating the prospective risk for PD in relation to baseline, follow-up periods ranged from 2–8 years.59–62 It has been demonstrated that olfactory dysfunction frequently precedes PD motor symptoms by more than 10 years;63 other studies have postulated that this period may last decades.65 A family history of PD in first- or second-degree relatives is known to be a serious risk factor. This is reflected by 33% development of PD in this patient group,63 and notably more in studies by Ponsen et al.59,60 and Berg et al.62 In contrast to quantitative smell loss, no association between qualitative smell disorders, such as parosmia or phantosmia, and future PD has been found (Table 1).63,66

From a practical view, it must be said, that the diagnostic utility of isolated olfactory testing for early diagnosis of PD has remained modest, considering the frequency of smell loss in the general population. However, if we look from a different perspective, the exclusion of the possibility of developing PD in a patient with unexplained olfactory loss appears statistically convincing. A data-driven approach, based on supervised machine-learning, identified certain parameters among patients with unexplained olfactory loss in order to detect future PD.67 These parameters comprised the three olfactory subtest results, in order of importance: odour discrimination, odour identification performance and olfactory threshold; in addition to whether the patient was aged >46 years when olfactory loss started and a family history of PD. Using these parameters, a negative predictive value of 94.1% for later PD development was found, which outperforms positive predictions in all available studies and strongly supports the utility of olfactory subtests (Figure 1).67

Concluding remarks

Olfactory loss in PD, including the observation that olfactory loss is an early clinical sign of the disease, has been acknowledged for many years. Current study results indicate a correlation between olfactory dysfunction and progression of PD as measured by motor and other non-motor symptoms, and suggest a very early onset of olfactory symptoms, in some patients even more than 10 years before the diagnosis. Despite an unquestionable involvement of olfactory symptoms in preclinical PD, the diagnostic utility of solitary olfactory testing only for early diagnosis has remained modest because of the high frequency of smell loss in the general population. This emphasizes the need for an exhaustive clinical assessment to ensure a correct diagnostic allocation of smell loss.

Article Information:
Disclosure

Since 2018 Thomas Hummel has conducted research together with, and received funding from, Sony, Stuttgart, Germany; Smell and Taste Lab, Geneva, Switzerland; Takasago, Paris, France and aspUraclip, Berlin, Germany. Antje Haehner and Heinz Reichmann have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Review Process

Double-blind peer review.

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Antje Haehner, Smell & Taste Clinic, Department of Otorhinolaryngology, TU Dresden, 01307 Dresden, Germany. E: antje.haehner@uniklinikum-dresden.de

Support

No funding was received in the publication of this article.

Access

This article is freely accessible at touchNEUROLOGY.com © Touch Medical Media 2020.

Received

2020-04-02

References

  1. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:79–84.
  2. Berendse HW, Roos DS, Raijmakers P, Doty RL. Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci. 2011;310:21–4.
  3. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44.
  4. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:436–46.
  5. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson’s disease – a multicenter study. Parkinsonism Relat Disord. 2009;15:490–4.
  6. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.
  7. Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol. 2008;63:7–15.
  8. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging2003;24:197–211.
  9. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord2015;30:350–8.
  10. Heintz-Buschart A, Pandey U, Wicke T, et al. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2018;33:88–98.
  11. Pereira PAB, Aho VTE, Paulin L, et al. Oral and nasal microbiota in Parkinson’s disease. Parkinsonism Relat Disord. 2017;38:61–7.
  12. Witt M, Bormann K, Gudziol V, et al. Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov Disord. 2009;24:906–14.
  13. Saito Y, Shioya A, Sano T, et al. Lewy body pathology involves the olfactory cells in Parkinson’s disease and related disorders. Mov Disord. 2016;31:135−8.
  14. Yousem DM, Geckle RJ, Bilker WB, et al. Posttraumatic olfactory dysfunction: MR and clinical evaluation. Am J Neuroradiol1996;17:1171–79.
  15. Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson’s disease a pilot study. J Neural Transm. 2005;112:1363–70.
  16. Rombaux P, Mouraux A, Bertrand B, et al. Olfactory function and olfactory bulb volume in patients with postinfectious olfactory loss. Laryngoscope. 2006;116:436–9.
  17. Rombaux P, Potier H, Bertrand B, et al. Olfactory bulb volume in patients with sinonasal disease. Am J Rhinol. 2008;22:598–601.
  18. Negoias S, Croy I, Gerber J, et al. Reduced olfactory bulb volume and olfactory sensitivity in patients with acute major depression. Neuroscience. 2010;169:415–21.
  19. Turetsky BI, Moberg PJ, Yousem DM, et al. Reduced olfactory bulb volume in patients with schizophrenia. Am J Psychiatry. 2000;157:828–30.
  20. Hummel T, Henkel S, Negoias S, et al. Olfactory bulb volume in patients with temporal lobe epilepsy. J Neurol. 2013;260:1004–8.
  21. Brodoehl S, Klingner C, Volk GF, et al. Decreased olfactory bulb volume in idiopathic Parkinson’s disease detected by 3.0-tesla magnetic resonance imaging. Mov Disord2012;27:1019–25.
  22. Chen S, Tan HY, Wu ZH, et al. Imaging of olfactory bulb and gray matter volumes in brain areas associated with olfactory function in patients with Parkinson’s disease and multiple system atrophy. Eur J Radiol. 2014;83:564–70.
  23. Altinayar S, Oner S, Can S, et al. Olfactory disfunction and its relation olfactory bulb volume in Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2014;18:3659–64.
  24. Hakyemez HA, Veyseller B, Ozer F, et al. Relationship of olfactory function with olfactory bulbus volume, disease duration and Unified Parkinson’s disease rating scale scores in patients with early stage of idiopathic Parkinson’s disease. J Clin Neurosci2013;20:1469–70.
  25. Mueller A, Rodewald A, Reden J, et al. Reduced olfactory bulb volume in post-traumatic and postinfectious olfactory dysfunction. Neuroreport. 2005;16:475–78.
  26. Paschen L, Schmidt N, Wolff S, et al. The olfactory bulb volume in patients with idiopathic Parkinson’s disease. Eur J Neurol. 2015;22:1068–73.
  27. Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord. 2004;19:687–92.
  28. Mundiñano IC, Caballero MC, Ordóñez C, et al. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol. 2011;122:61–74.
  29. Wattendorf E, Welge-Lüssen A, Fiedler K, et al: Olfactory impairment predicts brain atrophy in Parkinson’s disease. J Neurosci. 2009;29:15410–13.
  30. Wu X, Yu C, Fan F, et al. Correlation between progressive changes in piriform cortex and olfactory performance in early Parkinson’s disease. Eur Neurol. 2011;66:98–105.
  31. Lee EY, Eslinger PJ, Du G, et al. Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord2014;29:1205–8.
  32. Iannilli E, Stephan L, Hummel T, et al. Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline. J Neurol. 2017;264:1236–46.
  33. Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chron Dis. 1975;28:493–7.
  34. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson’s disease subtypes. Neurology. 1994;44:266–8.
  35. Iijima M, Kobayakawa T, Saito S, et al. Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol. 2011;18:425–9.
  36. Solla P, Masala C, Liscia A, et al. Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson’s disease. J Neurol. 2020;267:57–63.
  37. Melis M, Sollai G, Masala C, et al. Odor identification performance in idiopathic Parkinson’s disease is associated with gender and the genetic variability of the olfactory binding protein. Chem Senses2019;44:311–8.
  38. Herting B, Scholz S, Haehner A, et al. A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol. 2008;255:367–70.
  39. Masala C, Solla P, Liscia A, et al. Correlation among olfactory function, motors symptoms, cognitive impairment, apathy and fatigue in patients with Parkinson’s disease. J Neurol2018;265:1764–71.
  40. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM. 2010;103:941–52.
  41. Cavaco S, Gonçalves A, Mendes A, et al. Abnormal olfaction in Parkinson’s disease is related to faster disease progression. Behav Neurol. 2015:976589.
  42. Roos DS, Twisk JWR, Raijmakers PGHM, et al. Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease. J Neural Transm. 2019;126:1471–8.
  43. Whitcroft KL, Cuevas M, Haehner A, et al. Patterns of olfactory impairment reflect underlying disease etiology. Laryngoscope. 2017;127:291–5.
  44. Mahlknecht P, Pechlaner R, Boesveldt S, et al. Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson’s disease. Mov Disord. 2016;31:1408–13.
  45. Morley JF, Cohen A, Silveira-Moriyama L, et al. Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test. NPJ Parkinsons Dis. 2018;15;4:2.
  46. Hawkes CH, Shephard BC. Selective anosmia in Parkinson’s disease. Lancet. 1993;341:435–6.
  47. Daum RF, Sekinger B, Kobal G, et al. Olfactory testing with “sniffin’ sticks” for clinical diagnosis of Parkinson disease. Nervenarzt. 2000;71:643–50.
  48. Double KL, Rowe DB, Hayes M, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol. 2003;60:545–9.
  49. Hähner A, Maboshe W, Baptista R, et al. Selective hyposmia in Parkinson´s disease? J Neurol2013;260:3158–60.
  50. Roth J, Radil T, Ruzicka E, et al. Apomorphine does not influence olfactory thresholds in Parkinson’s disease. Funct Neurol. 1998;13:99–103.
  51. Rösser N, Berger K, Vomhof P, et al. Lack of improvement in odor identification by levodopa in humans. Physiol Behav. 2008;93:1024–9.
  52. Chaudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson’s disease. Prog Brain Res2010;184:325–41.
  53. Hummel T, Jahnke U, Sommer U, et al. Olfactory function in patients with idiopathic Parkinson’s disease: Effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm. 2005;112:669–76.
  54. Saatçi Ö, Yılmaz NH, Zırh A, et al. The therapeutic effect of deep brain stimulation on olfactory functions and clinical scores in Parkinson’s disease. J Clin Neurosci. 2019;68:55–61.
  55. Haehner A, Habersack A, Wienecke M, et al. Early Parkinson’s disease patients on rasagiline present with better odor discrimination. J Neural Transm. 2015;122:1541–6.
  56. Haehner A, Tosch C, Wolz M, et al. Olfactory training in patients with Parkinson’s disease. PLoS One. 2013;8:e61680.
  57. Knudsen K, Flensborg Damholdt M, Mouridsen K, et al. Olfactory function in Parkinson’s disease – effects of training. Acta Neurol Scand. 2015;132:395–400.
  58. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54:1–30.
  59. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–81.
  60. Ponsen MM, Stoffers D, Twisk JW, et al. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: a prospective study. Mov Disord. 2009;24:1060–5.
  61. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–73.
  62. Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol2013;20:102–8.
  63. Haehner A, Masala C, Walter S, et al. Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss. J Neurol. 2019;266:339–45.
  64. Gaig C, Tolosa E. When does Parkinson’s disease begin? Mov Disord. 2009;24(Suppl. 2):S656–64.
  65. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology. 2009;72(Suppl. 7):S21–6.
  66. Landis BN, Reden J, Haehner A. Idiopathic phantosmia: outcome and clinical significance. ORL J Otorhinolaryngol Relat Spec. 2010;72:252–5.
  67. Lötsch J, Haehner A, Hummel T. Machine-learning-derived rules set excludes risk of Parkinson’s disease in patients with olfactory or gustatory symptoms with high accuracy. J Neurol. 2020;267:469–78.

Further Resources

Share this Article
Related Content In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72